STOCK TITAN

Immunovant Inc - IMVT STOCK NEWS

Welcome to our dedicated news page for Immunovant (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunovant's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunovant's position in the market.

Rhea-AI Summary
Immunovant, Inc. (IMVT) secures U.S. Patent for IMVT-1402 until 2043, a promising antibody for autoimmune diseases. The patent covers composition of matter, methods of use, and manufacturing claims. IMVT-1402 shows potential best-in-class profile in Phase 1 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
-
Rhea-AI Summary
Immunovant, Inc. (IMVT) plans to initiate multiple registrational programs for IMVT-1402 and trials in 10 indications over the next fiscal years. The company reported promising Phase 1 data for IMVT-1402 and ongoing trials for batoclimab in various conditions. Financially, Immunovant ended the third quarter with a cash position of $691 million, with increased R&D and G&A expenses but a reduced net loss compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
earnings
-
Rhea-AI Summary
Immunovant, Inc. (Nasdaq: IMVT) CEO to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
conferences
Rhea-AI Summary
Immunovant, Inc. (Nasdaq: IMVT) announced that results from the initial cohort of patients in a 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease exceeded 50% response rates. The trial is assessing the safety and efficacy of batoclimab in patients who are hyperthyroid despite treatment with an anti-thyroid medication for more than 12 weeks. Initial results show potential best-in-class IgG reduction of up to 87% with a mean IgG reduction of 81% after 12 weeks of treatment. Batoclimab was generally well tolerated with no new safety signals observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.07%
Tags
clinical trial
-
Rhea-AI Summary
Immunovant, Inc. (IMVT) announced initial data from the 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults. The results show that four subcutaneously administered doses of 600 mg produced a mean IgG reduction similar to high dose batoclimab, but with minimal changes in albumin and LDL-C similar to those in placebo, confirming the potential of IMVT-1402 as a best-in-class neonatal FcRn inhibitor. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMVT-1402 in healthy adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
none
-
Rhea-AI Summary
Immunovant, Inc. (IMVT) CEO, Dr. Pete Salzmann, to participate in investor conferences, including Stifel 2023 Healthcare Conference, Evercore ISI 6th Annual HealthCONx Conference, and Piper Sandler 35th Annual Healthcare Conference. The fireside chats will be webcast live and can be accessed on Immunovant's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
conferences
Rhea-AI Summary
IMVT - Immunovant Reports Positive Initial Phase 1 Data for IMVT-1402, Raises $467M in Public Offering and Private Placement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.23%
Tags
earnings
-
Rhea-AI Summary
Immunovant, Inc. closes underwritten public offering of 8,475,500 shares of common stock at $38.00 per share, raising approximately $492.1 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
-
Rhea-AI Summary
Immunovant announces pricing of public offering and private placement, expecting gross proceeds of approximately $450 million. Public offering includes 7,370,000 shares at $38.00 per share, with an option for underwriters to purchase additional shares. Concurrent private placement with Roivant Sciences for 4,473,684 shares. Expected closing on or about October 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
Rhea-AI Summary
Immunovant announces proposed public offering and private placement of $300 million of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
Immunovant Inc

Nasdaq:IMVT

IMVT Rankings

IMVT Stock Data

4.72B
64.47M
55.5%
47.64%
5.98%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
New York

About IMVT

immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.